Etifoxine (EFX) is a non-benzodiazepine psychoactive drug which exhibits anxiolytic effects through 25 a dual mechanism, by directly binding to GABAA receptors (GABAARs) and to the mitochondrial 18-26 Page 5 of 37 Etifoxine (2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine hydrochloride, 91 EFX, Fig. 1 ) is a non-BZD compound that exhibits anxiolytic and anticonvulsant effects in rodents 92 [18] and is used for the treatment of anxiety-related disorders in humans [19,20]. EFX also displays 93 anti-hyperalgesic and anti-inflammatory properties in different animal models [21,22]. Both in vitro 94 and in vivo studies in rats suggested that the anxiolytic effects of EFX involve a dual mechanism of 95 action, by directly binding to central GABAARs and to the mitochondrial 18-kDa translocator protein 96 (TSPO) with, as a result, potentiation of the GABAergic function [23,24]. Indeed, it has been shown 97 that EFX activates TSPO through a direct binding and consecutively stimulates the synthesis of 98 neurosteroids, such as, allopregnanolone, which act as PAMs of GABAARs [25][26][27]. Although the 99 affinity of EFX for GABAARs was twice higher than the one for TSPO (Ki of 6.1 µM vs Ki of 12.7 100 µM), the predominance of one of the effect over the other, i.e. direct GABAARs binding or through 101 TSPO activation, in mediating its anxiolytic effect, is still debated [25,28,29].
Page 8 of 37 mouse had been included in a control group (not treated) from a previous protocol in which mice 149 were purchased from Janvier Labs (Le Genest-Saint-Isle, France). Euthanasia was performed using 150 CO2 (3 ml/min, 4 min). Adult female Xenopus laevis were purchased from CRB (Rennes, France) and 151 had been bred in the laboratory in strict accordance with the recommendations of the Guide for the 2.4 Anxiety-related behavioral assessment 174 Stress-induced hyperthermia (SIH) is defined as the increase in body temperature observed 175 when a subject is exposed to an external stressor [34] . The day preceding the experiment, the animals 176 were isolated in smaller cages (dimensions: 265x160x140 mm). The body temperature (± 0.1°C) of 177 one singly housed mouse was measured twice via a rectal probe (YSI n°423; 2 mm diameter) coupled 178 to a thermometer (Letica-Temp812 model-Italia) at an interval of 10 min. The rectal temperature 179 measurement procedure (handling, insertion of the probe) constitutes the stressor. Drugs were injected 180 60 min before the first measurement (T1), followed by a second temperature measurement 10 min 181 later (T2). Methodological experiments have shown that the optimal conditions for drug testing are 182 found with an injection-test interval of 60 min or longer to avoid residual effects of the injection 183 procedure. Indeed, using a 60 min-injection-stress interval results in a hyperthermic response 184 comparable to animals that are not injected [35, 36] . The reduction of SIH (∆T = T2-T1) is considered 185 to reflect an anxiolytic-like effect [34] [35] [36] . Defensive burying after novel object exploration is a 186 behavior that can be elicited in rodents in response to aversive or new stimuli [37] . Mice were singly 187 housed in smaller cages (see above) with a sawdust depth of 2.5 cm the day before the test. Each 188 mouse was confronted with an unfamiliar object (4x4x6 cm; aluminium) introduced in the centre of 189 the cage. The time of contact or exploring the object (snout pointing toward the object at a distance 190 < 1 cm with or without burying) was recorded for 10 min. The object was cleaned with alcohol (10%) 191 between each trial. This behavioral approach reveals an anxiety-like or fear state and its suppression 192 is associated with a reduction of the anxiety-like behavior [ subjected to melting and reannealing, as previously described [38] . Inserts containing GABAAR 244 subunit ORFs were also prepared in two individual PCRs (LIC-PCR1 and 2) with gene-specific primer pairs (see Table S1 in supplementary data). Sticky-end inserts were obtained as described for 246 the plasmid preparations. For each construct, sticky-ends plasmid and GABAA cDNA preparation 247 were assembled in T4 ligase buffer and incubated for 2 h at 22°C. One to two microliters of this 248 assemblage were used to transform chemically competent E. coli cells (DG1, Eurogentec, Seraing,
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Belgium). The resulting clones were sequenced as described above. Table S2 for receptor stoichiometry and DNA 259 quantity injected). Following injection, the oocytes were kept at 18°C in SOS supplemented with 260 gentamycin (50 μg/ml), penicillin (100 UI/ml), streptomycin (100 μg/ml), and sodium pyruvate 261 (2.5 mM). The incubation medium was replaced every two days. Oocytes were incubated 1 to 2 days 262 after DNA injection, depending on the GABAAR subtype. perfused at a flow rate close to ~4 ml/min. EFX and DZP were applied for 2 min before co-application 271 of GABA at EC10, (determined for each GABAAR subtype, see Table S2 in supplementary data) until 272 the current response peaked. EFX was tested at concentrations ranging from 2 to 100 μM, 273 corresponding to its clinical use. Between the two applications, the oocytes were washed in SOS for Fig. 2E ).
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The same was observed with EFX (H(3)=17.536, p<0.001), with a significant effect observed at doses 335 of 25 and 50 mg/kg compared with the control animals (p<0.05, Dunn's test) ( Fig. 2F ). In conclusion, 336 these two different behavioral tests led to similar anxiolytic doses of EFX (25-50 mg/kg, IP). 3.2 Motor performance assessment 370 We then compared the impact of EFX and BZP on locomotion performance and motor 371 coordination (Fig. 3) . As illustrated in Fig. 3 with the respective vehicle groups (see "data analysis and statistics" in the Material and Methods section). 387
EFX effects on GABA currents depends on α subunit isoforms 388
Because the distribution of GABAAR α subunits within the CNS is heterogeneous and 389 contributes to their receptor functions, we next investigated the involvement of α subunits in the EFX 390 mode of action using electrophysiology. To achieve this goal, we compared the effects of EFX (2 to 391 100 µM) on GABA-induced currents elicited by α1GABAARs, α2GABAARs, α3GABAARs, 392 α4GABAARs, α5GABAARs or α6GABAARs, containing β3 together with γ2S or d, when appropriate. 393 We first challenged EFX effects on GABA-currents elicited by synaptic α1β3γ2S, α2β3γ2S 394 and α3β3γ2S GABAARs expressed in Xenopus oocytes (Fig. 4) . We observed that EFX displays both agonist and potentiating effects as previously described [24] . The agonist effects of EFX were 396 revealed by its perfusion before co-application with GABA at EC10 (Table S2 ). EFX exhibits almost 397 no agonist effects on α1β3γ2S GABAARs (12.4 ± 5.8 and 23.7 ± 10.4 % of GABA EC10 at 50 and 100 398 µM EFX, respectively) ( Fig. 4A) . In contrast, comparable agonist effects were observed with 399 α2β3γ2S GABAARs (171 ± 24.9 % of GABA EC10, at 100 µM EFX, Fig. 4B ) and α3β3γ2S GABAARs 400 (153.6 ± 27.3% of GABA EC10, at 100 µM EFX, Fig. 4C ). In comparison with GABA, EFX exerted 401 weaker agonist effects (~100 fold less efficient). For these three receptors, EFX potentiation of GABA 402 EC10-evoked currents was dose-dependent, reaching a plateau at 50 µM ( Fig. 4) . At this concentration,
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EFX induced a potentiation of GABA EC10-evoked currents by 68.9 ± 11.6%, 160.3 ± 40.2% and Based on pharmacokinetic data [30], we estimated that 20 µM matches the concentration of 419 free EFX in the mouse brain after injection of anxiolytic doses (25-50 mg/kg, Fig. 2 ). Thus, we 420 compared agonist and potentiating effects of 20 µM EFX on α(1-3) β3γ2S GABAARs ( Fig. 5A and   421 B). EFX (20 µM) acts as a partial agonist on α2GABAARs and α3GABAARs, while these agonist 422 effects are not significant on α1GABAARs (Fig. 5A) . As for the potentiating effects, α3GABAARs 423 were much more sensitive to EFX (245.6 ± 41.8%) than α1 (50.1 ± 12.5%) and α2 (101.7 ± 12.2% 424 increase) -containing GABAARs (Fig. 5B ). In the synaptic cleft the GABA concentration rapidly rises 425 up to the millimolar range [48], we thus compared the GABA concentration-response relationships 426 in the presence and absence of 20 µM EFX at α1GABAARs, α2GABAARs and α3GABAARs (Fig. 5C , 427 Table 1 ). EFX induced a decrease of GABA EC50 with α1GABAARs and α2GABAARs in a similar 428 extent (~4-fold). In contrast, the GABA potency on α3GABAARs was increased by 20.6 ( Fig. 5C ).
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Taken together, our electrophysiological data show that, EFX behaves as a selective PAM of 430 α3GABAARs at concentration equivalent to anxiolytic doses. Next, we tested EFX on synaptic α4β3γ2S GABAARs and extrasynaptic α4β3d GABAARs. In 445 both cases, EFX did not exhibit any agonist effects nor significantly potentiate GABA-induced 446 currents, even at high concentrations (Fig. 6A,B) . Conversely, DZP at 2 µM enhanced GABA currents 447 elicited by α4β3γ2S GABAARs, as previously reported [49], but it did not affect α4β3d GABAARs 448 (Fig. 6A,B) . The extrasynaptic α5β3γ2S GABAARs appeared to be also insensitive to EFX at low 449 concentrations (2 and 20 µM), and weakly sensitive to EFX at 50 µM (54.26 ± 29.19%) ( Fig. 6C and 450 D). At 100 µM, EFX effects were significantly increased but did not reach a plateau (212.0 ± 31.97%).
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The α6 subunit was expressed with γ or d in accordance with the native GABAAR composition in the 452 cerebellum [50]. Similar agonist effects were observed with α6β3γ2S GABAARs (76.9 ± 20.3% of 453 GABA EC10, at 100 µM EFX,) and α6β3δ GABAARs (46.8 % of GABA EC10, at 100 µM EFX) (p=0.23,
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Mann and Whitney test) (Fig. 6E,F) as seen with α2GABAARs and α3GABAARs (Fig. 4B,C) . In conclusion, taking into account both agonist and potentiating EFX effects, GABAARs can 474 be ranked in three categories: i) resistant (α4GABAARs and α5GABAARs), ii) moderately sensitive 475 (α1GABAARs, α2GABAARs and α6GABAARs) and iii) highly sensitive (α3GABAARs) to EFX. 476 
Modelling of EFX-α3β3γ2s GABAAR interaction 477
To gain further insight into the mechanism of action of EFX, we generated a homology model 478 of α3β3γ2s GABAAR (Fig. 7A) to predict how EFX binds to its receptor site. The resulting computed 479 docking model was consistent with an EFX binding site located between α and β subunits in the 480 extracellular domain ( Fig. 7B and C) . The pocket found at the interface between α3 and β3 subunits, 481 homologous to the GABA binding sites, was large enough to accommodate EFX. Among the putative 482 binding modes, one was found in which EFX bound in the proximity of five amino acid residues of 483 the β3 subunit: N66, Y87, Q89, Y91 and R194 (Fig. 7D) . In α3 subunit, we identified two amino acid 484 residues (S257, S258) that may be involved in the EFX-GABAAR interaction. Two residues of β3, 485 N66 and R194, are conserved in β2 and β3 and are different in β1 subunits (R66 and N194). This pair 486 of amino acids might therefore control the binding mode of EFX as variations at these residues might 487 explain the subunit selectivity. 
Discussion
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The current study shows that a single administration EFX (25-50 mg/kg) induced a robust 498 anxiolytic behavior in mice subjected to stress-induced hyperthermia and novel object exploration 499 tests. In the same range of doses, and unlike classical BZDs, EFX did not evoke any secondary effects 500 in the spontaneous locomotor activity and rotarod performance. Pharmacokinetic data in Balb/cByJ 501 mice treated with anxiolytic doses indicated that EFX brain content reaches concentration range from 
EFX displays anxiolytic properties with weak side effects 512
Our findings confirm the anxiolytic properties of EFX at similar doses to those previously 513 used in other anxiety mouse models [30] . In comparison, EFX displays approximately 50-fold less 514 potent anxiolytic effects than BZP and DZP [8, 9] . However, both BZP and DZP strongly alter 515 locomotor performance and awakening at anxiolytic doses, while EFX does not. It is noteworthy that 516 pharmacokinetic factors involving, for example, active metabolites or differences in the extent of 517 metabolism could explain the differences in the effective doses of EFX and BZP. We reasoned that 518 BZDs, which have a high potency (submicromolar) for enhancing GABA-evoked currents, will 519 produce effects at a lower concentration than EFX which has a lower potency (micromolar) for 520 Page 28 of 37
GABAARs. Interestingly, EFX exhibits higher efficacy for α2GABAARs and α3GABAARs, known to 521 mediate anxiolytic effects (up to 171% and 410% for α2GABAARs and α3GABAARs, respectively) 522 than DZP (108% and 160% for α2GABAARs and α3GABAARs, respectively) [56] . 523 Compelling evidence indicates that the anxiolytic effects of BZP cannot be dissociated from 524 its sedative and myorelaxant effects, while the therapeutic margin is wider with EFX. In addition, 525 previous results have shown that EFX is devoid of amnesic effects at anxiolytic doses (50 mg/kg, IP Our electrophysiological data demonstrate that EFX behaves both as a partial agonist and a 551 PAM of GABAARs. In fact, EFX strongly potentiates GABA-evoked currents mediated by 552 α2GABAARs, α3GABAARs and/or α6GABAARs, with major effects on α3GABAARs in comparison to 553 any other GABAARs. This was also highlighted by a larger enhancement of the GABA potency on 554 α3GABAARs, than on α1GABAARs and α2GABAARs. However, the involvement of α3GABAARs in 555 anxiolysis is still a matter of debate. As mentioned above, there is still a controversy concerning the have revealed that this drug is not selective to α3GABAAR, but equally modulates GABA-evoked 564 currents mediated by α5GABAAR and also moderately potentiates α1GABAARs and α2GABAAR 565 [65,67]. TP003 was indeed shown to counteract anxiety behaviors in both rodents and squirrel 566 monkeys and thus highlights the medical use of α3GABAAR-selective molecules as efficient anxiolytics with no sedative secondary effects [14, 66] . Therefore, we believe that the anxiolytic-like 568 effects of EFX in mice are related to the modulation of α2GABAARs and α3GABAARs. Our objective was to challenge the possible influence of the α subunit for at least three reasons.
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First, β2 homopentamers are less sensitive to EFX than β3 homopentamers. However, when they are 572 combined with α1 or α2 subunits, the resulting binary GABAARs display a different pharmacological 573 profile: α1β2-3 and α2β2-3 GABAARs are equally potentiated, indicating that α1 and α2 subunits 574 modulate EFX potentiation [24] . Second, α1 and α2 subunits share a high amino acid sequence 575 identity, while α4-6 are structurally more distant [68] and thus could potentially have distinct 576 pharmacological influences. Here, we bring compelling evidences demonstrating that stimulating 577 effects of EFX are much stronger on α3β3γ2S than on α2β3γ2S, α6β3γ2S and α1β3γ2S GABAARs, 578 while α4β3γ2S and α5β3γ2S are almost insensitive. Altogether, our findings indicate a strong 579 regulatory effect of the α subunit on EFX mode of action. 580 We also examined the involvement of γ2S and d subunits in the mode of action of EFX and 581 we observed that α4β3γ2S and α4β3d on one hand, α6β3γ2S and α6β3d GABAARs on the other hand, 582 are equally sensitive to EFX. This reinforces the idea that, unlike BZDs [7], the third subunit is not 583 involved in the EFX-GABAAR interaction.
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Consecutively, we hypothesized that EFX site is likely located between the α and β subunits.
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Our 3D docking simulation suggests that EFX binds in a pocket at the α/β subunit interface 586 homologous to the GABA binding pocket recently described [69], highlighting putative amino acid 587 residues involved in EFX binding. Interestingly, among them, two residues of β3, N66 and R194, are 588 conserved in β2 and β3 and differ in the β1 subunits (R66 and N194). This pair of amino acids may 589 belong to the binding site of EFX and summarise its subunit selectivity. Site-directed mutagenesis 590 experiments are required to validate this hypothesis and to define the residues underlying the EFX
